Nifty
:
14521.15
Sensex
:
49398.29
239.85 (1.68%)
834.02 (1.72%)
Nifty
Sensex
:
:
14521.15
49398.29
239.85 (1.68%)
834.02 (1.72%)

Glenmark Pharmaceuticals Ltd.

Pharmaceuticals & Drugs - Global

Rating :
58/99

BSE: 532296 | NSE: GLENMARK

NSE BSE
504.35
19-Jan-2021
  • Open
  • High
  • Low
  • Previous Close
  •  499.00
  •  506.70
  •  496.05
  •  496.25
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  1171344
  •  5876.30
  •  573.05
  •  161.65

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 13,991.31
  • 15.57
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 17,759.99
  • 0.50%
  • 2.16

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 46.63%
  • 1.24%
  • 15.40%
  • FII
  • DII
  • Others
  • 25.79%
  • 3.56%
  • 7.38%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 13.69
  • 7.07
  • 5.45

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.11
  • 3.39
  • 1.00

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 5.53
  • 0.87
  • -1.17

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 22.09
  • 17.98
  • 15.98

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.87
  • 3.72
  • 2.45

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 14.03
  • 11.71
  • 9.84

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 20
Sep 19
Var%
Jun 20
Jun 19
Var%
Mar 20
Mar 19
Var%
Dec 19
Dec 18
Var%
Net Sales
2,952.48
2,815.04
4.88%
2,344.79
2,322.88
0.94%
2,767.49
2,563.47
7.96%
2,735.56
2,555.05
7.06%
Expenses
2,399.67
2,364.63
1.48%
1,866.72
1,980.97
-5.77%
2,301.80
2,199.34
4.66%
2,295.49
2,120.37
8.26%
EBITDA
552.81
450.41
22.73%
478.07
341.91
39.82%
465.69
364.13
27.89%
440.08
434.68
1.24%
EBIDTM
18.72%
16.00%
20.39%
14.72%
14.01%
14.01%
16.09%
17.01%
Other Income
-31.88
80.83
-
58.51
1.67
3,403.59%
44.14
39.06
13.01%
32.96
-109.02
-
Interest
80.63
89.77
-10.18%
93.74
93.02
0.77%
98.47
81.91
20.22%
96.06
88.53
8.51%
Depreciation
104.07
94.16
10.52%
113.22
90.73
24.79%
126.28
80.97
55.96%
106.00
83.10
27.56%
PBT
339.38
347.30
-2.28%
357.61
159.83
123.74%
317.96
240.31
32.31%
270.98
154.03
75.93%
Tax
105.38
91.76
14.84%
103.57
50.55
104.89%
97.65
78.65
24.16%
80.14
37.69
112.63%
PAT
233.99
255.54
-8.43%
254.04
109.28
132.47%
220.31
161.66
36.28%
190.84
116.34
64.04%
PATM
7.93%
9.08%
10.83%
4.70%
7.11%
7.11%
6.98%
4.55%
EPS
8.29
9.06
-8.50%
9.00
3.87
132.56%
28.29
28.29
0.00%
6.76
4.12
64.08%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Net Sales
10,800.32
10,640.97
9,865.47
9,074.42
9,079.41
7,561.67
6,680.94
5,944.95
4,969.14
4,020.64
2,949.07
Net Sales Growth
5.30%
7.86%
8.72%
-0.05%
20.07%
13.18%
12.38%
19.64%
23.59%
36.34%
 
Cost Of Goods Sold
7,419.52
3,623.78
3,283.71
2,963.32
2,552.03
2,246.58
1,538.25
1,785.62
1,584.70
1,291.00
951.07
Gross Profit
3,380.80
7,017.18
6,581.76
6,111.10
6,527.39
5,315.09
5,142.69
4,159.33
3,384.44
2,729.65
1,998.00
GP Margin
31.30%
65.94%
66.72%
67.34%
71.89%
70.29%
76.98%
69.96%
68.11%
67.89%
67.75%
Total Expenditure
8,863.68
8,942.89
8,279.67
7,459.05
7,042.71
6,124.52
5,466.62
4,854.17
3,953.86
3,306.28
2,356.82
Power & Fuel Cost
-
173.69
165.25
137.47
127.02
120.47
109.11
93.50
80.13
0.00
0.00
% Of Sales
-
1.63%
1.68%
1.51%
1.40%
1.59%
1.63%
1.57%
1.61%
0%
0%
Employee Cost
-
2,254.78
2,056.07
1,871.84
1,640.81
1,378.19
1,212.61
1,026.15
782.95
628.89
510.17
% Of Sales
-
21.19%
20.84%
20.63%
18.07%
18.23%
18.15%
17.26%
15.76%
15.64%
17.30%
Manufacturing Exp.
-
669.50
725.16
648.59
546.75
956.59
1,323.66
336.59
272.53
54.40
40.76
% Of Sales
-
6.29%
7.35%
7.15%
6.02%
12.65%
19.81%
5.66%
5.48%
1.35%
1.38%
General & Admin Exp.
-
1,168.32
891.10
526.29
1,022.89
491.20
253.29
859.67
678.94
1,331.99
854.82
% Of Sales
-
10.98%
9.03%
5.80%
11.27%
6.50%
3.79%
14.46%
13.66%
33.13%
28.99%
Selling & Distn. Exp.
-
1,005.63
1,125.08
996.99
1,064.70
892.67
991.23
524.25
521.00
0.00
0.00
% Of Sales
-
9.45%
11.40%
10.99%
11.73%
11.81%
14.84%
8.82%
10.48%
0%
0%
Miscellaneous Exp.
-
47.19
33.29
314.55
88.52
38.82
38.48
228.40
33.61
0.00
0.00
% Of Sales
-
0.44%
0.34%
3.47%
0.97%
0.51%
0.58%
3.84%
0.68%
0%
0%
EBITDA
1,936.65
1,698.08
1,585.80
1,615.37
2,036.70
1,437.15
1,214.32
1,090.78
1,015.28
714.36
592.25
EBITDA Margin
17.93%
15.96%
16.07%
17.80%
22.43%
19.01%
18.18%
18.35%
20.43%
17.77%
20.08%
Other Income
103.73
159.60
208.14
91.40
37.37
20.00
6.88
11.48
10.75
18.17
144.41
Interest
368.90
377.32
334.58
285.57
237.32
178.88
190.15
188.59
160.01
146.57
160.46
Depreciation
449.57
417.17
325.90
301.88
264.37
234.28
300.41
216.79
127.01
97.88
94.68
PBT
1,285.93
1,063.20
1,133.45
1,119.33
1,572.38
1,043.98
730.63
696.88
739.00
488.09
481.54
Tax
386.74
320.11
375.64
315.46
382.68
300.94
334.07
151.27
110.72
23.78
23.70
Tax Rate
30.07%
29.20%
28.88%
28.18%
25.66%
28.83%
61.46%
21.71%
14.98%
4.87%
4.92%
PAT
899.18
775.97
924.98
803.78
1,108.80
743.23
209.54
542.27
620.03
460.35
453.20
PAT before Minority Interest
899.08
775.97
924.99
803.87
1,108.75
743.04
209.47
545.60
628.29
464.31
457.83
Minority Interest
-0.10
0.00
-0.01
-0.09
0.05
0.19
0.07
-3.33
-8.26
-3.96
-4.63
PAT Margin
8.33%
7.29%
9.38%
8.86%
12.21%
9.83%
3.14%
9.12%
12.48%
11.45%
15.37%
PAT Growth
39.88%
-16.11%
15.08%
-27.51%
49.19%
254.70%
-61.36%
-12.54%
34.69%
1.58%
 
EPS
31.86
27.50
32.78
28.48
39.29
26.34
7.43
19.22
21.97
16.31
16.06

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Shareholder's Funds
6,070.51
5,605.18
5,163.48
4,492.52
3,629.64
1,783.49
2,983.28
2,763.03
2,401.63
2,037.24
Share Capital
28.22
28.22
28.22
28.22
28.22
27.13
27.12
27.09
27.05
27.03
Total Reserves
6,028.59
5,566.35
5,124.75
4,462.86
3,599.98
1,756.36
2,956.16
2,735.94
2,374.58
2,010.21
Non-Current Liabilities
3,033.01
2,279.94
2,824.12
3,257.81
1,499.40
2,749.09
1,966.58
1,625.13
1,137.64
519.01
Secured Loans
0.00
0.00
0.00
0.00
0.00
0.00
2,428.66
1,920.30
1,312.47
617.07
Unsecured Loans
4,042.99
3,573.75
4,141.78
4,536.34
2,487.30
2,574.38
0.00
0.00
0.00
0.00
Long Term Provisions
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
14.58
6.90
Current Liabilities
4,125.98
4,021.09
3,287.89
2,702.68
3,999.25
3,776.71
2,949.17
2,201.39
1,901.74
2,259.06
Trade Payables
2,125.84
2,220.75
1,869.78
1,743.22
1,940.79
1,948.04
1,362.58
1,036.94
788.83
657.41
Other Current Liabilities
1,001.63
1,013.21
690.60
509.32
1,137.01
1,264.30
973.31
763.41
414.83
109.80
Short Term Borrowings
442.60
303.02
295.04
187.19
787.42
347.60
353.32
367.82
687.46
1,480.23
Short Term Provisions
555.91
484.11
432.46
262.95
134.03
216.78
259.95
33.22
10.63
11.62
Total Liabilities
13,229.11
11,905.83
11,275.12
10,452.59
9,127.99
8,309.10
7,912.31
6,613.91
5,466.01
4,842.01
Net Block
5,028.56
3,670.25
3,029.55
2,755.09
2,593.55
2,015.38
2,889.66
2,406.26
2,237.30
2,066.62
Gross Block
8,269.83
6,527.27
5,367.95
4,769.92
4,300.54
3,495.47
3,632.62
2,934.90
2,650.96
2,383.39
Accumulated Depreciation
3,241.28
2,857.01
2,338.39
2,014.83
1,706.99
1,480.09
742.96
528.63
413.66
316.77
Non Current Assets
6,425.49
5,209.02
4,286.43
3,577.96
3,223.69
2,978.04
3,149.61
2,887.10
2,518.85
2,243.24
Capital Work in Progress
1,221.89
1,398.94
1,121.87
708.11
542.79
477.13
206.24
422.31
248.33
145.70
Non Current Investment
24.59
29.66
14.66
15.69
17.20
17.12
0.00
0.00
0.00
0.00
Long Term Loans & Adv.
123.97
94.36
119.78
98.94
69.99
468.16
33.39
36.52
0.00
0.00
Other Non Current Assets
26.49
15.80
0.56
0.13
0.16
0.27
20.33
22.00
33.23
30.92
Current Assets
6,803.62
6,696.82
6,988.69
6,874.64
5,904.30
5,331.06
4,762.69
3,726.81
2,947.15
2,598.77
Current Investments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
2,135.62
2,252.07
2,030.59
2,139.05
1,567.76
1,269.04
932.88
843.53
787.67
807.01
Sundry Debtors
2,408.96
2,194.59
2,331.81
2,404.32
2,492.65
2,511.76
2,156.34
1,640.05
1,243.61
1,130.81
Cash & Bank
1,111.24
937.76
1,234.69
1,057.66
857.12
775.88
800.67
607.31
321.92
195.83
Other Current Assets
1,147.78
765.22
810.78
683.39
986.77
774.38
872.81
635.91
593.95
465.11
Short Term Loans & Adv.
544.48
547.18
580.83
590.22
594.89
742.94
768.44
540.03
518.90
322.39
Net Current Assets
2,677.63
2,675.73
3,700.80
4,171.96
1,905.05
1,554.35
1,813.53
1,525.42
1,045.41
339.71
Total Assets
13,229.11
11,905.84
11,275.12
10,452.60
9,127.99
8,309.10
7,912.30
6,613.91
5,466.00
4,842.01

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Cash From Operating Activity
1,392.41
1,324.17
1,648.05
657.43
344.85
481.68
853.73
647.93
804.39
930.58
PBT
1,096.08
1,300.63
1,119.33
1,491.43
1,043.98
543.54
696.88
739.00
488.09
481.55
Adjustment
636.23
329.83
571.28
726.56
391.03
522.76
709.78
342.45
484.05
189.65
Changes in Working Capital
127.06
136.34
309.06
-861.51
-611.96
-266.82
-290.07
-268.49
-34.79
353.13
Cash after chg. in Working capital
1,859.37
1,766.81
1,999.67
1,356.48
823.05
799.49
1,116.58
812.96
937.35
1,024.34
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-466.95
-442.63
-351.61
-699.05
-478.20
-317.81
-262.86
-165.03
-132.96
-93.75
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-783.52
-698.99
-1,013.34
-712.35
-880.17
-540.04
-368.10
-464.06
-277.79
-367.27
Net Fixed Assets
-248.78
455.14
-362.24
-256.09
-286.93
-1,354.84
-112.12
-178.05
-54.88
-40.77
Net Investments
-1,445.18
-56.07
-1,345.98
-8.28
-198.90
-250.28
-114.91
-211.06
-42.02
-48.33
Others
910.44
-1,098.06
694.88
-447.98
-394.34
1,065.08
-141.07
-74.95
-180.89
-278.17
Cash from Financing Activity
-444.66
-738.74
-468.50
543.15
698.60
199.22
-98.02
195.24
-361.39
-435.61
Net Cash Inflow / Outflow
164.23
-113.56
166.21
488.24
163.27
140.86
387.61
379.11
165.21
127.70
Opening Cash & Equivalents
936.28
1,233.36
1,056.36
857.12
763.74
794.80
605.18
320.08
194.87
103.58
Closing Cash & Equivalent
1,110.28
936.28
1,233.36
1,056.36
857.12
763.74
794.80
605.18
320.08
194.87

Financial Ratios

Consolidated /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Book Value (Rs.)
214.65
198.27
182.62
159.16
128.59
65.74
109.99
102.01
88.77
75.38
ROA
6.17%
7.98%
7.40%
11.33%
8.52%
2.58%
7.51%
10.40%
9.01%
9.47%
ROE
13.32%
17.21%
16.67%
27.31%
27.46%
8.79%
18.99%
24.33%
20.92%
20.85%
ROCE
14.04%
16.47%
14.77%
20.54%
18.53%
12.40%
15.04%
17.67%
14.44%
15.34%
Fixed Asset Turnover
1.44
1.66
1.80
2.03
1.96
1.90
1.83
1.79
1.60
1.29
Receivable days
78.95
83.73
94.95
97.29
119.39
125.97
115.37
104.99
107.78
136.71
Inventory Days
75.25
79.22
83.59
73.65
67.68
59.42
53.99
59.39
72.38
93.78
Payable days
98.44
97.43
96.28
101.59
117.03
95.22
83.15
68.48
108.47
106.73
Cash Conversion Cycle
55.77
65.53
82.26
69.35
70.04
90.17
86.21
95.91
71.69
123.76
Total Debt/Equity
0.80
0.80
0.90
1.05
1.10
2.13
1.10
1.00
0.93
1.03
Interest Cover
3.90
4.89
4.92
7.28
6.84
3.86
4.70
5.62
4.33
4.00

Annual Reports:

FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014
FY 2013
FY 2012
FY 2011

News Update:


  • Glenmark gets tentative nod for Gabapentin Enacarbil Extended-Release Tablets, Apremilast Tablets
    31st Dec 2020, 10:34 AM

    The Horizant market achieved annual sales of approximately $99.5 million

    Read More
  • Glenmark Pharmaceuticals gets USFDA’s nod for Tadalafil Tablets
    31st Dec 2020, 09:50 AM

    The Cialis Tablets, 2.5 mg, 5 mg, 10 mg and 20 mg market achieved annual sales of approximately $125.5 million

    Read More
  • Glenmark becomes first company to launch Remogliflozin + Vildagliptin fixed dose combination
    29th Dec 2020, 13:12 PM

    The fixed drug combination is indicated for the management of Type 2 diabetes

    Read More
  • Glenmark Pharmaceuticals’ arm enters into licensing agreement with Menarini Group
    23rd Dec 2020, 09:36 AM

    Glenmark will be responsible for the continued development and regulatory approval of Ryaltris in these markets

    Read More
  • Glenmark Pharmaceuticals gets tentative approval for Dabigatran Etexilate Capsules
    21st Dec 2020, 10:40 AM

    The 12 month period ending October 2020, the Pradaxa Capsules, 75 mg, 110 mg, and 150 mg market achieved annual sales of approximately $550.9 million

    Read More
  • Glenmark Pharmaceuticals’ arm gets tentative approval for Axitinib Tablets
    1st Dec 2020, 10:46 AM

    The company has received tentative approval by the United States Food & Drug Administration

    Read More
  • Glenmark to divest select brands to Dr Reddy’s in Russia, Ukraine, Kazakhstan and Uzbekistan
    30th Nov 2020, 09:16 AM

    The company has entered into a definitive agreement with Dr. Reddy’s for the same

    Read More
  • Glenmark secures position in Dow Jones Sustainability Emerging Markets Index
    26th Nov 2020, 12:58 PM

    The DJSI analyses companies on their corporate economic, environmental and social performance

    Read More
  • Glenmark Pharmaceuticals’ arm gets USFDA’s nod for Tacrolimus Capsules
    11th Nov 2020, 09:37 AM

    Glenmark’s current portfolio consists of 166 products authorized for distribution in the U.S. marketplace and 45 ANDA’s pending approval with the USFDA

    Read More
  • Glenmark Pharma reports 8% fall in consolidated net profit in Q2
    7th Nov 2020, 09:46 AM

    Total consolidated income of the company marginally increased by 0.85% at Rs 2920.60 crore for Q2FY21

    Read More
  • Glenmark Pharma - Quarterly Results
    6th Nov 2020, 21:02 PM

    Read More
  • Glenmark Pharmaceuticals’ arm gets USFDA’s nod for Sirolimus Tablets
    19th Oct 2020, 10:31 AM

    Glenmark’s current portfolio consists of 165 products authorized for distribution in the U.S. marketplace and 45 ANDA’s pending approval with the U.S. FDA

    Read More
  • Glenmark launches Nintedanib capsules for treatment of pulmonary fibrosis in India
    14th Oct 2020, 09:59 AM

    The company is being a leader in the area of respiratory has been amongst the first to launch the branded generic version at an affordable cost

    Read More
  • Glenmark Pharma reports no significant clinical benefit with Umifenovir
    12th Oct 2020, 16:17 PM

    This was the second clinical study after the successful Favipiravir monotherapy trial earlier this year that led the company to receiving the Emergency use Authorisation for Favipiravir

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.